Publicaciones (34) Publicaciones de José Luis Ordóñez García

2023

  1. Renal Sympathetic Hyperactivity in Diabetes Is Modulated by 5-HT1D Receptor Activation via NO Pathway

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

2022

  1. CRISPR/Cas9‐Directed Gene Trap Constitutes a Selection System for Corrected BCR/ABL Leukemic Cells in CML

    International Journal of Molecular Sciences, Vol. 23, Núm. 12

2021

  1. Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression

    Blood Cancer Journal, Vol. 11, Núm. 7

  2. CRISPR-Cas9 Technology as a Tool to Target Gene Drivers in Cancer: Proof of Concept and New Opportunities to Treat Chronic Myeloid Leukemia

    CRISPR Journal, Vol. 4, Núm. 4, pp. 519-535

2020

  1. CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition

    Leukemia, Vol. 34, Núm. 6, pp. 1599-1612

  2. ETV6/RUNX1 Fusion Gene Abrogation Decreases the Oncogenicity of Tumour Cells in a Preclinical Model of Acute Lymphoblastic Leukaemia

    Cells, Vol. 9, Núm. 1

2019

  1. Preclinical efficacy of endoglin-targeting antibody–drug conjugates for the treatment of Ewing sarcoma

    Clinical Cancer Research, Vol. 25, Núm. 7, pp. 2228-2240

2017

  1. Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin [Oncotarget, 6, (2015), (18875-18890)]. doi: 10.18632/oncotarget.4303

    Oncotarget

  2. The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia

    Oncotarget, Vol. 8, Núm. 16, pp. 26027-26040

2016

  1. Molecular pathology of bone and soft tissue tumors

    The Molecular Basis of Human Cancer (Springer New York), pp. 623-655

  2. Proteomic Profiling of Ewing Sarcoma Reveals a Role for TRAF6 in Proliferation and Ribonucleoproteins/RNA Processing

    Journal of Proteomics & Bioinformatics, Vol. 09, Núm. 06

2015

  1. Molecular Genetics of Ewing Sarcoma

    eLS, pp. 1-11

  2. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

    Oncotarget, Vol. 6, Núm. 22, pp. 18875-18890

  3. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents

    Clinical Cancer Research, Vol. 21, Núm. 6, pp. 1373-1382

2014

  1. Characterization of human mesenchymal stem cells from Ewing sarcoma patients. Pathogenetic implications

    PLoS ONE, Vol. 9, Núm. 2

  2. Innovative therapies in ewing sarcoma

    Advances in Anatomic Pathology, Vol. 21, Núm. 1, pp. 44-62

2013

  1. Fluorescence in situ hybridization analysis of CCND3 gene as marker of progression in bladder carcinoma

    Journal of Biological Regulators and Homeostatic Agents, Vol. 27, Núm. 2, pp. 559-567

  2. The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis

    Carcinogenesis, Vol. 34, Núm. 2, pp. 268-276

  3. WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells

    Oncogene, Vol. 32, Núm. 11, pp. 1441-1451

2012

  1. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma

    Oncogene, Vol. 31, Núm. 10, pp. 1287-1298